Cargando…

Body Mass Index, Disease Duration and Tumor Necrosis Factor Inhibitor History Predict Reduced Ustekinumab Response in Chinese Psoriasis Patients: A Real-World Study

BACKGROUND: Ustekinumab, as a monoclonal antibody against interleukin (IL)-12 and IL-23, gets approved in China since 2019, therefore fewstudies report the application of ustekinumab in treating Chinese psoriasis patients in the real clinical settings until now. AIMS: Thus, this study aimed to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xue, Qin, Guifang, Meng, Zudong, Pei, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751685/ https://www.ncbi.nlm.nih.gov/pubmed/35068529 http://dx.doi.org/10.4103/ijd.IJD_232_21

Ejemplares similares

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
por: Elberdín, Laida, et al.
Publicado: (2022)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Influence of ustekinumab on body weight of patients with psoriasis: an initial report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2014)

Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study
por: Pirro, Federico, et al.
Publicado: (2021)

Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
por: Pan, Shan, et al.
Publicado: (2020)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Ustekinumab Biotherapy and Real-Time Psoriasis Capacitance Mapping: A Pilot Study
por: Piérard-Franchimont, Claudine, et al.
Publicado: (2012)

Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients
por: E, Cailing, et al.
Publicado: (2021)

Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab
por: Zhao, Yue, et al.
Publicado: (2014)

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
por: Van Kuijk, Arno W R, et al.
Publicado: (2023)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
por: Youn, Sang Woong, et al.
Publicado: (2016)

Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice
por: Galache Osuna, Cristina, et al.
Publicado: (2020)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
por: Chien, Tzu Hsiang, et al.
Publicado: (2021)

Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis
por: Uchida, Genta, et al.
Publicado: (2023)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Genome-Wide Association Study of Ustekinumab Response in Psoriasis
por: Connell, William T., et al.
Publicado: (2022)

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
por: Yang, Seungkeol, et al.
Publicado: (2021)

Associations between body mass index and severity of psoriasis
por: Sobhan, Mohammadreza, et al.
Publicado: (2017)

Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis
por: Ghazanfar, Misbah N., et al.
Publicado: (2019)

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
por: Krulig, Eliana, et al.
Publicado: (2010)

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
por: Hermanns-Lê, Trinh, et al.
Publicado: (2012)

Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
por: Kim, Ye Seul, et al.
Publicado: (2016)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Listeria Meningitis in a Patient With Plaque Psoriasis on Ustekinumab Therapy
por: Roy, Moni, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
por: Jung, Seung-Won, et al.
Publicado: (2022)

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
por: Hoffmann, Peter, et al.
Publicado: (2019)

Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
por: Yao, Jia-yin, et al.
Publicado: (2021)

Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
por: Avgerinou, Georgia, et al.
Publicado: (2012)

The use of ustekinumab in a patient with severe psoriasis and positive HBV serology()
por: Steglich, Raquel Bissacotti, et al.
Publicado: (2014)

Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab
por: Jayasekera, Prativa S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_58uidj3h7a76c49li7pn27ct34